Healthcare
Monday, August 29, 2016
BRIEF-Nymox says new phase 3 long-term U.S.results for fexapotide show major decrease in prostate cancer
* Nymox's new Phase 3 long-term U.S. results for prostate
enlargement drug fexapotide show decrease in prostate cancer
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment